Andrea S. Blevins Primeau, PhD, MBA

Investigators sought to evaluate the role of mean heart disease and left anterior descending dose in predicting the risk of major cardiac adverse events in patients with non-small cell lung cancer.

Investigators aimed to characterize the heterogeneity in PD-L1 expression among different histologic patterns of metastases of lung adenocarcinoma.

Investigators conducted an integrated analysis of phase 1 and 2 trials assessing the efficacy of entrectinib among patients with ROS1 fusion-positive non-small cell lung cancer

A team of investigators conducted a retrospective study to assess outcomes with the use of chemotherapy in patients 80 years of age and older diagnosed with metastatic non-small cell lung cancer.

The open-label, phase 3 TAHOE trial assessed outcomes in patients with previously treated, DLL3-high advanced or metastatic small lung cancer treated with rovalpituzumab tesirine or topotecan.

A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.

A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.

A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.

The goal of the TRANSFORMER study was to compare the effects of bipolar androgen therapy with enzalutamide in asymptomatic men with castration-resistant prostate cancer who have experienced disease progression while receiving treatment with abiraterone.

Extensive examination of lymph nodes and node stations should be used to predict accurate staging and survival outcomes in patients with radiologically pure-solid non-small cell lung cancer.